香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 茲提述星太鏈集團有限公司（「本公司」）日期為二零二五年十月十三日的公告（「該 公告」），內容有關日期為二零二五年十月十三日有關代幣發行之諒解備忘錄。 除文義另有指明外，本公告所用詞彙與該公告所界定者具有相同涵義。 本公司謹此補充有關代幣發行的資料，本公司將委聘專注於數字資產的香港 法律顧問，以就代幣發行的分類及架構提供意見，包括但不限於所涉及的私隱 考慮及排除代幣分派可能受限制的司法權區股東或替代機制。如有需要，本公 司亦將委聘擁有相關牌照的分銷商或代理協助代幣發行。除非及直至本公司 已取得所有必要意見及確認，指代幣發行在所有方面均符合所有適用法律法規， 否則本公司將不會進行代幣發行。 於本公告日期，本公司正就代幣發行進行法律審核及諮詢，尚未與監管機關展 開任何諮詢。董事會將密切留意事態發展及任何私隱或利益衝突事宜，以確保 在所有時候均妥為遵守所有監管程序。 本公司將於適當時候及倘此事項有任何重大進展 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 STARCOIN GROUP LIMITED 星太鏈集團有限公司 （前稱領航醫藥及生物科技有限公司） （於開曼群島註冊成立並於百慕達存續之有限公司） （股份代號：399） 進一步延長最後截止日期 茲提述星太鏈集團有限公司（前稱領航醫藥及生物科技有限公司）（「本公司」） 日期為二零二五年七月十五日、二零二五年七月十六日、二零二五年八月五日、 二零二五年八月二十六日、二零二五年九月十六日及二零二五年十月六日的 公告（統稱「該等公告」），內容有關張彪兵及陳靜按每股認購股份0.3124港元的 認購價分別認購本公司60,000,000股股份及30,000,000股股份。除文義另有規定 外，本公告所用詞彙與該等公告所界定者具有相同涵義。 認購協議B 根據認購協議B（經補充協議B及日期為二零二五年八月五日、二零二五年八月 二十六日、二零二五年九月十六日及二零二五年十月六日的延長函件修訂及 補充），倘先決條件未能於二 ...

Core Viewpoint - The company clarifies that it has not signed any merger agreement with Tianxingjian Health Industry Group, contrary to claims made in a recent media article [1] Group 1 - The company’s board became aware of a media article published on October 16, 2025, titled "Tianxingjian Group - Star Chain Hong Kong Stock Merger Announcement" [1] - The article falsely claims that the company has entered into a merger agreement with Tianxingjian [1] - The company asserts that it has no relationship, connection, or affiliation with Tianxingjian [1] Group 2 - The company reserves the right to take legal action against the media and/or individuals responsible for publishing false information [1] - The company will consider other appropriate legal remedies to protect its interests and those of its shareholders [1]

Group 1 - The company clarifies that it has not signed any merger agreement with Tianxingjian Health Industry Group [1] - The article published on October 16, 2025, falsely claims that the company has entered into a merger agreement [1] - The company reserves the right to take legal action against the media or individuals responsible for disseminating false information [1]

Core Viewpoint - The company clarifies that it has not signed any merger agreement with Tianxingjian Health Industry Group and has no relationship with them [1] Group 1 - The company issued a statement to address a misleading article published on October 26, 2025, claiming a merger announcement with Tianxingjian [1] - The company reserves the right to take legal action against the media or individuals responsible for disseminating false information [1] - The company aims to protect its interests and those of its shareholders through appropriate legal remedies if necessary [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 STARCOIN GROUP LIMITED 星太鏈集團有限公司 （前稱領航醫藥及生物科技有限公司） （於開曼群島註冊成立並於百慕達存續之有限公司） （股份代號：399） 有關網上媒體文章的 澄清公告 本公告由星太鏈集團有限公司（「本公司」，連同其附屬公司，統稱「本集團」）發 佈，旨在澄清二零二五年十月十六日網上媒體刊載題為「《天行健集團—星太 鏈港股併購公告》發佈會」的文章「該文章」。 本公司董事會得知，該文章聲稱本公司已與天行健健康產業集團（「天行健」） 簽訂併購協議。本公司謹此澄清，該文章內容不屬實。本公司並無與天行健簽 訂任何併購協議，與天行健亦無任何關係、聯繫或隸屬關係。 本公司保留對刊載含有不實資料的該文章的媒體及╱或相關人士採取法律行 動的權利，並將視情況採取其他適當法律補救措施，以保障本公司及其股東的 權益。 – 1 – – 2 – 茲建議股東及潛在投資者不要依賴有關本集團的市場傳言。 ...

Group 1 - The company has signed two memorandums of understanding (MOUs) to explore new business opportunities in blockchain technology and digital innovation [1][2] - The first MOU is with Supernova, focusing on developing and managing blockchain-based systems and related token issuance under applicable U.S. laws, as well as representing Supernova in projects related to AQP functional water technology [1][2] - The second MOU is with Scaling Lab, aimed at collaborating on scientific research related to the genetic epidemiology and physiology of cardiovascular diseases and their risk factors, particularly diabetes [1][2] Group 2 - The company is actively seeking to diversify its revenue sources and enhance performance through strategic plans, including expanding into the blockchain technology sector [2] - The collaboration with Supernova is expected to facilitate entry into the digital innovation industry and develop a new business segment [2] - The partnership with Scaling Lab is intended to strengthen the company's diabetes solution development and support the exploration of new business opportunities [2]

Group 1 - The company has signed two memorandums of understanding (MOUs) to explore collaborations in blockchain technology and health-related research [1][2] - The first MOU is with Supernova, focusing on developing and managing blockchain-based systems and token issuance under applicable U.S. laws, as well as representing Supernova in projects related to AQP functional water technology [1][2] - The second MOU is with Scaling Lab, aimed at scientific research collaboration on genetic epidemiology and physiology of cardiovascular diseases, particularly concerning diabetes and its treatment methods [1][2] Group 2 - The company is an investment holding firm actively seeking new business opportunities to diversify revenue sources and enhance performance [2] - The collaboration with Supernova is intended to advance the company's entry into the digital innovation sector, indicating a strategic move towards blockchain technology [2] - The partnership with Scaling Lab is expected to strengthen the company's research capabilities in diabetes solutions and support the exploration of new business opportunities [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部份內容而產生 或因倚賴該等內容而引致之任何損失承擔任何責任。 STARCOIN GROUP LIMITED 星太鏈集團有限公司 （前稱領航醫藥及生物科技有限公司） （於開曼群島註冊成立並於百慕達存續之有限公司） （股份代號：399） 自願公告 (I) 有關潛在合作的諒解備忘錄；及 (II) 有關潛在機構研究的諒解備忘錄 本公告乃由本公司自願作出。 董事會欣然宣佈，於二零二五年十月十六日（聯交所交易時段後），本公司已 訂立以下兩份諒解備忘錄： (I) 有關潛在合作的諒解備忘錄 於二零二五年十月十六日（聯交所交易時段後），本公司與Supernova訂立 第一份諒解備忘錄，內容有關有意就本公司與Supernova之間之合作設立 框架，以(i)根據適用美國法律及法規開發及管理基於區塊鏈之系統及相 關代幣發行；及(ii)作為Supernova於有關AQP功能水技術及Supernova擁有 的相關生物技術之機構合作項目之指定代表。 – 1 – (II) 有關潛在機構研究的諒 ...

Core Viewpoint - Starcoin Foundation intends to issue Starcoin tokens, with a distribution model based on existing shareholdings in the company, marking a significant step in integrating traditional finance with blockchain technology [1][2] Group 1: Company Overview - Starcoin Foundation is a non-profit organization established under the laws of the Republic of Panama, focusing on smart contract key management, DAO governance, and token custody for project development and operations [1] - The company has entered into a memorandum of understanding with Starcoin Foundation to initiate a token issuance project, which is the first of its kind directly initiated and recognized by a listed company in Asia [1] Group 2: Token Issuance Details - The token issuance will be based on a model where shareholders will receive one Starcoin token for every ten existing shares held, establishing a direct link between traditional equity and digital assets [1] - Each Starcoin token will be backed by USD assets, aiming to create an integrated on-chain investment banking system focused on the issuance, compliance, and global circulation of real-world assets (RWA) [1] Group 3: Technological Integration - The company plans to leverage blockchain technology to reshape traditional financial processes, aiming to become a key connector between global assets and digital investors [2] - The token issuance will be deployed on the Conflux eSpace public blockchain, enhancing the project's technological foundation [2]